These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
432 related articles for article (PubMed ID: 23897954)
1. Patterns of Recurrence and outcome according to breast cancer subtypes in lymph node-negative disease: results from international breast cancer study group trials VIII and IX. Metzger-Filho O; Sun Z; Viale G; Price KN; Crivellari D; Snyder RD; Gelber RD; Castiglione-Gertsch M; Coates AS; Goldhirsch A; Cardoso F J Clin Oncol; 2013 Sep; 31(25):3083-90. PubMed ID: 23897954 [TBL] [Abstract][Full Text] [Related]
2. Breast cancer subtype approximations and loco-regional recurrence after immediate breast reconstruction. Kneubil MC; Brollo J; Botteri E; Curigliano G; Rotmensz N; Goldhirsch A; Lohsiriwat V; Manconi A; Martella S; Santillo B; Petit JY; Rietjens M Eur J Surg Oncol; 2013 Mar; 39(3):260-5. PubMed ID: 23313014 [TBL] [Abstract][Full Text] [Related]
3. Outcomes and recurrence patterns according to breast cancer subtypes in Korean women. Lee Y; Kang E; Lee AS; Baek H; Kim EK; Park SY; Kim JH; Kim YJ; Kim SH; Kim IA; Eom KY; Kim SW Breast Cancer Res Treat; 2015 May; 151(1):183-90. PubMed ID: 25893592 [TBL] [Abstract][Full Text] [Related]
4. Long-Term Outcomes of Immunohistochemically Defined Subtypes of Breast Cancer Less Than or Equal to 2 cm After Breast-Conserving Surgery. Pata G; Guaineri A; Bianchi A; Amoroso V; Pasinetti N; Pasini M J Surg Res; 2019 Apr; 236():288-299. PubMed ID: 30694768 [TBL] [Abstract][Full Text] [Related]
5. Prognostic Significance of Progesterone Receptor Expression in Estrogen-Receptor Positive, HER2-Negative, Node-Negative Invasive Breast Cancer With a Low Ki-67 Labeling Index. Ono M; Tsuda H; Yoshida M; Shimizu C; Kinoshita T; Tamura K Clin Breast Cancer; 2017 Feb; 17(1):41-47. PubMed ID: 27477822 [TBL] [Abstract][Full Text] [Related]
6. Biological Characteristics and Long-term Outcomes in Node-negative Breast Cancer. Agostinetto E; Giordano L; Torrisi R; De Sanctis R; Masci G; Losurdo A; Zuradelli M; Tinterri C; Gatzemeier W; Testori A; Alloisio M; De Rose F; Fernandes B; Santoro A Clin Breast Cancer; 2020 Aug; 20(4):e481-e489. PubMed ID: 32279915 [TBL] [Abstract][Full Text] [Related]
7. Histological grade provides significant prognostic information in addition to breast cancer subtypes defined according to St Gallen 2013. Ehinger A; Malmström P; Bendahl PO; Elston CW; Falck AK; Forsare C; Grabau D; Rydén L; Stål O; Fernö M; Acta Oncol; 2017 Jan; 56(1):68-74. PubMed ID: 27762648 [TBL] [Abstract][Full Text] [Related]
8. A divergent role for estrogen receptor-beta in node-positive and node-negative breast cancer classified according to molecular subtypes: an observational prospective study. Novelli F; Milella M; Melucci E; Di Benedetto A; Sperduti I; Perrone-Donnorso R; Perracchio L; Venturo I; Nisticò C; Fabi A; Buglioni S; Natali PG; Mottolese M Breast Cancer Res; 2008; 10(5):R74. PubMed ID: 18771580 [TBL] [Abstract][Full Text] [Related]
9. The influence of breast cancer subtype on survival after palliative radiation for osseous metastases. Abdelhakiem MK; Johnstone C; Bergom C; Currey A; Robbins JR Cancer Med; 2020 Dec; 9(23):8979-8988. PubMed ID: 33146466 [TBL] [Abstract][Full Text] [Related]
10. Platelet/Lymphocyte Ratio Is Superior to Neutrophil/Lymphocyte Ratio as a Predictor of Chemotherapy Response and Disease-free Survival in Luminal B-like (HER2 Hu Y; Wang S; Ding N; Li N; Huang J; Xiao Z Clin Breast Cancer; 2020 Aug; 20(4):e403-e409. PubMed ID: 32201163 [TBL] [Abstract][Full Text] [Related]
11. Failure patterns according to molecular subtype in patients with invasive breast cancer following postoperative adjuvant radiotherapy: long-term outcomes in contemporary clinical practice. Lim YJ; Lee SW; Choi N; Kwon J; Eom KY; Kang E; Kim EK; Kim SW; Kim JH; Kim YJ; Kim SH; Park SY; Kim JS; Kim IA Breast Cancer Res Treat; 2017 Jun; 163(3):555-563. PubMed ID: 28315066 [TBL] [Abstract][Full Text] [Related]
12. Basal-like immunophenotype markers and prognosis in early breast cancer. Cassol L; Silveira Graudenz M; Zelmanowicz A; Cancela A; Werutsky G; Rovere RK; Garicochea B Tumori; 2010; 96(6):966-70. PubMed ID: 21388060 [TBL] [Abstract][Full Text] [Related]
13. [Survival of patients with metastatic breast cancer according to pathological types of tumors]. Sánchez R C; Acevedo C F; Petric G M; Galindo A H; Domínguez C F; León R A; Razmilic V D; Ceballos C; Espinoza F; Navarro O ME; Oddó B D; Camus A M Rev Med Chil; 2014 Apr; 142(4):428-35. PubMed ID: 25117032 [TBL] [Abstract][Full Text] [Related]
14. High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller. Gonzalez-Angulo AM; Litton JK; Broglio KR; Meric-Bernstam F; Rakkhit R; Cardoso F; Peintinger F; Hanrahan EO; Sahin A; Guray M; Larsimont D; Feoli F; Stranzl H; Buchholz TA; Valero V; Theriault R; Piccart-Gebhart M; Ravdin PM; Berry DA; Hortobagyi GN J Clin Oncol; 2009 Dec; 27(34):5700-6. PubMed ID: 19884543 [TBL] [Abstract][Full Text] [Related]
15. Pattern of Local Recurrence and Distant Metastasis in Breast Cancer By Molecular Subtype. Wu X; Baig A; Kasymjanova G; Kafi K; Holcroft C; Mekouar H; Carbonneau A; Bahoric B; Sultanem K; Muanza T Cureus; 2016 Dec; 8(12):e924. PubMed ID: 28090417 [TBL] [Abstract][Full Text] [Related]
16. Body weight and risk of molecular breast cancer subtypes among postmenopausal Mediterranean women. Crispo A; Montella M; Buono G; Grimaldi M; D'Aiuto M; Capasso I; Esposito E; Amore A; Nocerino F; Augustin LS; Giudice A; Di Bonito M; Giuliano M; Forestieri V; De Laurentiis M; Rinaldo M; Ciliberto G; De Placido S; Arpino G Curr Res Transl Med; 2016; 64(1):15-20. PubMed ID: 27140595 [TBL] [Abstract][Full Text] [Related]
17. Prognosis in women with small (T1mic,T1a,T1b) node-negative operable breast cancer by immunohistochemically selected subtypes. Cancello G; Maisonneuve P; Rotmensz N; Viale G; Mastropasqua MG; Pruneri G; Montagna E; Dellapasqua S; Iorfida M; Cardillo A; Veronesi P; Luini A; Intra M; Gentilini O; Scarano E; Goldhirsch A; Colleoni M Breast Cancer Res Treat; 2011 Jun; 127(3):713-20. PubMed ID: 21452022 [TBL] [Abstract][Full Text] [Related]
18. Effect of adjuvant chemotherapy in patients with ER + /HER2- breast cancer, assessed by propensity score matching: significance of nuclear grade and nodal status. Tanaka N; Hirano A; Hattori A; Ogura K; Kamimura M; Inoue H; Yukawa H; Sakaguchi S; Matsuoka A; Kodera A; Shimizu T Breast Cancer; 2021 Jan; 28(1):40-47. PubMed ID: 32592141 [TBL] [Abstract][Full Text] [Related]
19. Characteristics and outcomes according to molecular subtypes of breast cancer as classified by a panel of four biomarkers using immunohistochemistry. Park S; Koo JS; Kim MS; Park HS; Lee JS; Lee JS; Kim SI; Park BW Breast; 2012 Feb; 21(1):50-7. PubMed ID: 21865043 [TBL] [Abstract][Full Text] [Related]
20. Absolute Benefit of Adjuvant Endocrine Therapies for Premenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer: TEXT and SOFT Trials. Regan MM; Francis PA; Pagani O; Fleming GF; Walley BA; Viale G; Colleoni M; Láng I; Gómez HL; Tondini C; Pinotti G; Price KN; Coates AS; Goldhirsch A; Gelber RD J Clin Oncol; 2016 Jul; 34(19):2221-31. PubMed ID: 27044936 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]